Ranitidine and Optic ischaemic neuropathy - a phase IV clinical study of FDA data

Summary:

Optic ischaemic neuropathy is reported as a side effect among people who take Ranitidine (ranitidine), especially for people who are male, 60+ old, also take Zantac, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Optic ischaemic neuropathy when taking Ranitidine. It is created by eHealthMe based on reports of 233,168 people who have side effects when taking Ranitidine from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Optic ischaemic neuropathy?

Optic ischaemic neuropathy (optic nerve damage due to lack of blood supply) is found to be associated with 258 drugs and 484 conditions by eHealthMe. Check the latest studies of Optic ischaemic neuropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

233,168 people reported to have side effects when taking Ranitidine.
Among them, 22 people (0.01%) have Optic ischaemic neuropathy.

Could Ranitidine cause Optic ischaemic neuropathy?

Among these 22 people:

What is the gender of people who have Optic ischaemic neuropathy when taking Ranitidine? *

  • female: 50 %
  • male: 50 %

What is the age of people who have Optic ischaemic neuropathy when taking Ranitidine? *

  • 0-1: 15 %
  • 2-9: 0.0 %
  • 10-19: 5 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 15 %
  • 50-59: 25 %
  • 60+: 40 %

What are other drugs people take besides Ranitidine? *

  1. Zantac: 5 people, 22.73%
  2. Optivar: 4 people, 18.18%
  3. Norco: 4 people, 18.18%
  4. Metoprolol Tartrate: 4 people, 18.18%
  5. Simvastatin: 4 people, 18.18%
  6. Venclexta: 4 people, 18.18%
  7. Digoxin: 3 people, 13.64%
  8. Cartia Xt: 3 people, 13.64%
  9. Morphine Sulfate: 3 people, 13.64%
  10. Lipitor: 3 people, 13.64%

What are other side effects people have besides Optic ischaemic neuropathy? *

  1. Blindness: 7 people, 31.82%
  2. Oedema Peripheral (superficial swelling): 6 people, 27.27%
  3. Hypophagia (reduced food intake): 5 people, 22.73%
  4. Hypotension (abnormally low blood pressure): 5 people, 22.73%
  5. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 18.18%
  6. Back Pain: 4 people, 18.18%
  7. Abdominal Distension: 3 people, 13.64%
  8. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 3 people, 13.64%
  9. Cough: 3 people, 13.64%
  10. Delirium (wild excitement): 3 people, 13.64%

What are the existing conditions these people have? *

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 4 people, 18.18%
  2. Polycythaemia (proportion of blood volume that is occupied by red blood cells increases): 3 people, 13.64%
  3. Heart Rate Irregular: 3 people, 13.64%
  4. Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 3 people, 13.64%
  5. Pulmonary Vascular Resistance Abnormality: 2 people, 9.09%
  6. Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 9.09%
  7. Multiple Myeloma (cancer of the plasma cells): 2 people, 9.09%
  8. Escherichia Sepsis (bacterial infection by escherichia coli): 2 people, 9.09%
  9. Psoriasis (immune-mediated disease that affects the skin): 1 person, 4.55%
  10. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and have Optic ischaemic neuropathy?

- Check whether Optic ischaemic neuropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ranitidine:

Optic ischaemic neuropathy treatments and more:

How severe was Optic ischaemic neuropathy and when was it recovered:

Expand to all the drugs that have ingredients of ranitidine:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic ischaemic neuropathy:

Browse all the conditions that are associated with Optic ischaemic neuropathy:


How the study uses the data?

The study uses data from the FDA. It is based on ranitidine (the active ingredients of Ranitidine) and Ranitidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: